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Abstract
Several previous studies have investigated the role of common promoter variants in the vascular endothelial growth factor
(VEGF) gene in causing congenital cardiovascular malformation (CVM). However, results have been discrepant between
studies and no study to date has comprehensively characterised variation throughout the gene. We genotyped 771 CVM
cases, of whom 595 had the outflow tract malformation Tetralogy of Fallot (TOF), and carried out TDT and case-control
analyses using haplotype-tagging SNPs in VEGF. We carried out a meta-analysis of previous case-control or family-based
studies that had typed VEGF promoter SNPs, which included an additional 570 CVM cases. To identify rare variants
potentially causative of CVM, we carried out mutation screening in all VEGF exons and splice sites in 93 TOF cases. There was
no significant effect of any VEGF haplotype-tagging SNP on the risk of CVM in our analyses of 771 probands. When the
results of this and all previous studies were combined, there was no significant effect of the VEGF promoter SNPs rs699947
(OR 1.05 [95% CI 0.95–1.17]); rs1570360 (OR 1.17 [95% CI 0.99–1.26]); and rs2010963 (OR 1.04 [95% CI 0.93–1.16]) on the risk
of CVM in 1341 cases. Mutation screening of 93 TOF cases revealed no VEGF coding sequence variants and no changes at
splice consensus sequences. Genetic variation in VEGF appears to play a small role, if any, in outflow tract CVM susceptibility.
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Introduction
Congenital cardiovascular malformation (CVM) occurs in
approximately 7 out of every 1000 live births [1], and is the
commonest cause of death in childhood in developed countries.
CVM is defined as a gross structural abnormality of the heart or
intrathoracic great vessels that is present at birth and is of
functional significance. The incidence figure quoted above
excludes bicuspid aortic valve, which is present in 1–2% of live
births, but is usually not detected until much later in life, if at all.
Though some 20% of cases of CVM can be attributed to specific
causes such as chromosomal disorders, recognised multi-organ
syndromes and teratogen exposure, the majority of cases are
assumed to result from a complex interaction of environmental
and genetic factors [2,3]. In support of this notion, substantial
genetic influences have been inferred for certain malformations in
studies of familial recurrence risk ascertained through non-
syndromic patients [4]. However, as yet relatively few candidate
genes have been systematically investigated for any possible
contribution of common variants to disease risk.
Vascular endothelial growth factor (VEGF) plays an important
role in the formation of the endocardial cushions during heart
development, and either up- or down-regulation of VEGF
expression can result in CVM in experimental models [5–14].
Genotypes at the common VEGF promoter SNPs rs699947 and
rs1570360, and the 59UTR SNP rs2010963 are associated with
inter-individual differences in VEGF expression levels in vitro
[15,16]. Genotypes and haplotypes at these SNPs that are
associated with lower VEGF production were first associated with
the risk of CVM in a study which compared 58 patients with
microdeletion of 22q11 and CVM with 316 healthy controls. This
suggested that VEGF could act as a genetic modifier of the cardiac
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confirmed in a trio-based study of 148 non-syndromic patients
with the outflow tract malformation Tetralogy of Fallot (TOF); no
association was found in that study among 40 trios containing a
proband with transposition of the great arteries [17]. It was
therefore suggested that the VEGF haplotypes had a specific
association with TOF. TOF is a particularly important CVM sub-
phenotype for genetic study since it is the commonest complex
cyanotic heart defect (which invariably requires corrective surgery
in early life), and familial recurrence risk studies have shown
particularly strong evidence for genetic effects. A subsequent study
comparing 102 patients with non-syndromic valvular and/or
septal defects of the heart and 112 controls found no association
between genotype at a proxy SNP for rs699947 and CVM, and
found association in the opposite direction to the previous studies
between the rs2010963 SNP and CVM [18]. Most recently, the
genotypes and haplotypes associated with lower VEGF expression
were associated with disease risk in a study of 222 Chinese patients
with Ventricular Septal Defect (VSD) and 352 controls [19]. Data
from the literature is only available in 570 patients at present, and
estimates of the population attributable risk (PAR) of CVM arising
from common genetic variation in VEGF range from 0.11 to 0.48
in previous studies (our calculations). More precise estimates of
these potentially important genetic risks are therefore required
from larger studies and pooled analyses of available data. We have
carried out a comprehensive characterisation of common variants
in VEGF which more than doubles the number of CVM cases
studied thus far. We have combined the results of this study and all
previous studies in a meta-analysis. Our primary dataset includes a
large number of cases with the outflow tract malformation TOF,
which should enable us to address the potential sub-phenotypic
specificity of the previously published association securely.
Since CVM has historically been a condition with a high
perinatal and childhood mortality, it is evolutionarily plausible that
low-frequency, intermediate-penetrance variants could make at
least as significant a contribution to the population genetic risk as
common variants. However, no previous study has systematically
carried out mutation screening of the VEGF gene in CVM cases.
We therefore also carried out exonic and splice site resequencing
in 93 TOF cases to identify whether individually rare variants in
VEGF collectively make a significant contribution to TOF risk.
The hypotheses tested by this study were therefore twofold: first,
that common genetic variants in VEGF were associated with the
occurrence of non-syndromic, non-Mendelian CVM (in particu-
lar, TOF); and second, that rarer variants affecting amino-acid
sequence or consensus splice sites were associated with the
occurrence of non-syndromic, non-Mendelian TOF.
Results
The founder genotypes for twenty VEGF Haplotype-tagging
SNPs (htSNPs) were shown to be in Hardy-Weinberg equilibrium
(p.0.01). Genotype and haplotype frequencies were in good
agreement with HapMap data, for those markers where it was
available, and with previous published studies. The likelihood ratio
statistics and associated p-values from the UNPHASED analysis of
the twenty VEGF htSNPs in both TOF and non-TOF CVM
families and controls are shown in Table 1. None of the SNPs
showed a significant association with CVM in 357 TOF cases.
When the three previously reported SNPs (rs699947, rs1570360,
rs2010963) were genotyped in an additional 238 TOF cases, there
remained no significant association in the total of 595 TOF cases.
Similarly, none of the VEGF htSNPs showed significant
association with CVM risk in the 176 cases with non-TOF
CVM. Although borderline significant (p=0.035–0.037) evidence
for association was observed at rs1547651 and rs3025035 in the
non-TOF CVM patients, this seems unlikely to reflect true
association when multiple comparisons are taken into account.
The three SNPs reported in previous studies to show association
with CVM (rs699947, rs1570360, and rs2010963) were also
analysed as a three-marker haplotype in the 595 TOF probands
and the 176 CVM probands using UNPHASED. There was no
association between any of the four haplotypes and either TOF or
non-TOF CVM (Table 2).
The search strategy identified four previous studies, all of which
were suitable for inclusion in the meta-analysis. Genotype
frequencies were either stated to, or could be calculated to
conform to, Hardy-Weinberg equilibrium in all studies. Genotype
frequencies were generally in good agreement between the studies,
although the study by Vannay et al. [18] showed a significantly
different allele frequency at the rs2010963 SNP in controls from
that observed in the other studies or from dbSNP data for subjects
of European ancestry. Vannay et al. [18] typed SNP rs833061
(referred to in that study as T-460C) which was not typed in other
studies; however, HapMap data from the CEU population
indicates that this is an almost perfect proxy SNP for rs699947
(D9=1;r
2=0.965) and therefore the rs833061 SNP data from that
study was pooled with the data for rs699947 derived from the
other studies. The study by Lambrechts et al. [17] contained sub-
populations with TOF and transposition of the great arteries; odds
ratios were calculated separately for each population for each SNP
before pooling. The study by Xie et al. [19] included 222 cases
Table 1. Association analysis of VEGF genotypes.
SNP TOF (357) TOF (595) CVM (176)
LR p-value LR p-value LR p-value
rs833052 0.88 0.65 1.30 0.52
rs866236 0.18 0.91 3.72 0.16
rs833057 0.65 0.72 1.93 0.38
rs1547651 0.37 0.83 6.72 0.04
rs833058 0.11 0.95 0.25 0.89
rs699946 0.11 0.95 0.50 0.78
rs699947 2.29 0.32 1.70 0.43 0.48 0.79
rs1570360 3.14 0.21 3.90 0.14 0.93 0.63
rs2010963 0.36 0.84 1.29 0.53 3.64 0.16
rs2146323 0.81 0.67 1.52 0.47
rs3025000 0.07 0.97 3.37 0.19
rs3025033 0.76 0.69 0.11 0.95
rs3025035 0.48 0.79 6.61 0.04
rs9369421 0.32 0.85 3.30 0.19
rs879825 0.07 0.97 1.75 0.42
rs1358980 3.60 0.17 0.84 0.66
rs1885658 0.20 0.91 1.66 0.44
rs1885659 1.43 0.49 1.44 0.49
rs10948095 0.62 0.73 0.39 0.82
rs13210960 0.38 0.83 0.51 0.77
Likelihood Ratio (LR) Chi-Squared statistics with associated probabilities (p-
value) for ‘UNPHASED’ analysis of VEGF genotypes in the 357 and 595 TOF
families and 176 CVM families; three previously reported SNPs are shown in
bold.
doi:10.1371/journal.pone.0004978.t001
VEGF Gene and CVM
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controls; of the 222 cases in that study 142 had parents available.
Xie et al. [19] carried out TDT testing in that subgroup, obtaining
slightly more extreme odds ratios (but wider confidence intervals)
in the smaller dataset. We carried out pooled analyses including
either the case/control comparison or the TDT subgroup from
that study; there was no material difference in the conclusions
whichever population was included (data available on request). We
therefore principally quote the analyses including the larger
dataset of 222 cases and 352 unrelated controls from Xie et al.
[19]. The pooled analyses contain information on 1341 CVM
cases, of whom 743 have TOF, 540 have non-TOF CVM, and 58
have CVM associated with 22q11 deletion. Removal of the 58
patients with CVM and 22q11 deletion did not, as expected given
their small numbers, alter any of the conclusions of the pooled
analyses.
The pooled analysis for rs699947 yielded a combined OR for
CVM of 1.05 (95% CI 0.95–1.17) in all patients, 1.02 (95% CI
0.88–1.18) in patients with TOF, and 1.04 (95% CI 0.88–1.22) in
patients with non-TOF CVM for the A allele associated with risk
in smaller studies (Table 3). As can be inferred from the 95% CIs,
none of these associations were statistically significant at the
p,0.05 level. The maximum plausible PAR associated with this
SNP for all CVM was calculated as 0.08. The pooled analysis for
rs1570360 yielded a combined OR for CVM of 1.12 (95% CI
0.99–1.26) in all patients, 1.09 (95% CI 0.93–1.27) in patients with
TOF, and 1.03 (95% CI 0.84–1.27) in patients with non-TOF
CVM for the A allele (Table 4). None of these associations were
statistically significant, and the maximum plausible PAR associ-
ated with this SNP for all CVM was 0.08. The pooled analysis for
rs2010963 yielded a combined OR for CVM of 1.04 (95% CI
0.93–1.16) in all patients, 0.99 (95% CI 0.85–1.15) in patients with
TOF, and 1.07 (95% CI 0.90–1.26) in patients with non-TOF
CVM for the G allele. None of these associations were statistically
significant, and the maximum plausible PAR associated with this
SNP for all CVM was 0.09 (Table 5).
To determine whether low frequency, intermediate penetrance
genetic variants in VEGF might predispose in particular to
Tetralogy of Fallot, the exonic and splice site regions of the gene
were re-sequenced in a panel of 93 cases, all of whom had TOF.
The two previously reported SNPs rs2010963 and rs25648 were
detected in the 59UTR of exon 1 in a proportion of patients,
consistent with previously available data; however, no new coding
sequence variants or splice site consensus sequence were identified.
Simple binomial probabilities indicate that if such variants were
present in as few as 5% of patients in the population with TOF,
resequencing of 93 cases would have a greater than 90% power to
detect at least one occurrence.
Discussion
Thisstudydoes not support the hypothesisthat eithercommonor
rare genetic variation in VEGF significantly predisposes to the risk
of CVM. Our primary data with respect to common variation has
more than doubled the amount of information hitherto available in
the literature. Pooled analysis of our primary data and previous
Table 2. Association analysis of three-marker VEGF haplotype.
TOF (595)
Haplotype Case Control Ca-Freq Co-Freq OR 95%Low 95%High
LR 4.11 A-A-G* 389 352 0.33 0.33 1.00 1.00 1.00
df 3 A-G-G 181 182 0.15 0.17 0.85 0.67 1.07
p-value 0.25 C-G-C
{ 399 332 0.34 0.31 1.07 0.89 1.29
C-G-G 205 190 0.17 0.18 0.94 0.76 1.17
CVM (176)
Haplotype Case Control Ca-Freq Co-Freq OR 95%Low 95%High
LR 4.63 A-A-G* 111 189 0.32 0.32 1.00 1.00 1.00
df 3 A-G-G 62 104 0.18 0.18 0.85 0.54 1.35
p-value 0.20 C-G-C
{ 101 196 0.29 0.33 0.75 0.51 1.11
C-G-G 72 100 0.21 0.17 1.16 0.77 1.74
Likelihood Ratio (LR) Chi-Squared statistics with associated probabilities (p-value); estimated allele counts and frequencies in cases and controls (Ca-Freq, Co-Freq); and
odds ratios with 95% confidence intervals from ‘UNPHASED’ analysis of VEGF rs699947 (22578A/C)/ rs1570360 (21154A/G) / rs2010963 (2634C/G) haplotype in the 595
TOF families and 176 CVM families are presented.
*Haplotype 22578A/21154A/2634G, previously reported by Lambrechts et al. (2005) and Stalmans et al. (2003) to increase risk of TOF and CVM.
{Haplotype 22578C/21154G/2634C, previously reported by Xie et al. (2007) to be protective against VSD.
doi:10.1371/journal.pone.0004978.t002
Table 3. Pooled analysis of rs699947: A allele of C/A SNP
designated high risk.
Study
No.
Probands OR 95%CI Low 95% CI High
Stalmans 58 1.50 1.00 2.30
Lambrechts TOF 148 1.43 1.03 1.97
Lambrechts TGA 40 1.13 0.57 2.21
Vannay 102 0.79 0.54 1.15
Xie Case-Control (all) 222 1.18 0.89 1.56
Xie TDT only 142 1.08 0.74 1.56
Present study TOF patients595 0.93 0.79 1.10
Present study other CVM 176 1.04 0.80 1.35
All studies* 1341 1.05 0.96 1.17
*Pooled ORs include the entire population of cases and controls from Xie et al.
(2007) rather than the subset of TDT families.
doi:10.1371/journal.pone.0004978.t003
VEGF Gene and CVM
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any of the three previously typed SNPs in the promoter and 59
region of VEGF with CVM. Furthermore, our analyses show no
evidence for a specific effect of VEGF SNPs on the risk of TOF, an
important CVM sub-phenotype previously claimed to be particu-
larly strongly associated with the VEGF polymorphisms we have
typed. Resequencing of the exonicand splicesite regionsof VEGF in
a panel of 93 cases with TOF did not identify any mutations
changing amino acids or splice site consensus sequences, suggesting
that such mutations could at most account for a very small
proportion of the population risk of TOF.
Previous studies had suggested association between VEGF SNPs
and CVM; however, numbers of cases in previous studies were
small and the confidence intervals around the odds ratio estimates
correspondingly large. The data from previous studies suggested
that the PAR of SNPs in VEGF was between 0.11 and 0.48, which
if the upper estimate were correct would indicate that a very
substantial degree of population morbidity and mortality from
CVM is directly due to genetic variability in VEGF. However,
when our primary data is pooled with the results of previous
studies, we show that the maximum plausible PAR from these
VEGF SNPs is in fact less than 10%. Very large studies involving
several thousand cases would be required to exclude effects of only
a few percent on risk. Lambrechts et al. [17] reported an
association between the low VEGF expression haplotype compris-
ing the A, A, and G alleles at rs699947, rs1570360 and rs2010963
respectively and disease risk in 148 TOF trio families. This study
genotyped the same SNPs in a total of 595 TOF probands, 237 of
which were trio families, and found no significant over
transmission of the low-expression AAG haplotype. The comple-
mentary CGC haplotype at these SNPs was reported by Xie et al.
[19] to be under-transmitted to 364 probands with VSD. Xie et al.
[19] studied a larger number of VSD cases than were present in
our primary data, and therefore a protective effect of the CGC
haplotype that is specific to VSD cannot be entirely ruled out. The
data reported by Vannay et al. [18] was generated in patients with
valvuloseptal defects which would very likely have included a high
proportion of VSDs; however, no detailed phenotypic breakdown
of patients is available in that paper. Moreover, it was not possible
to infer the corresponding haplotype frequencies from the data
presented in Vannay et al. [18], which precluded a comprehensive
haplotype-based meta-analysis of all published data. With respect
to our resequencing experiment, no previous similar study has
been conducted so far; we resequenced sufficient patients to
determine that amino-acid or splice-site altering mutations could
at the most account for only a few percent of the population risk of
disease.
Animalmodelshave demonstrated that VEGF mustbe expressed
within a physiological window for normal embryonic development,
particularly of the heart, to occur [5–12,14]. The mouse Vegf-164
isoform is crucial for cardiac development and a reduction or
absence in expression severely perturbs epithelial to mesenchymal
transformation and cardiac cushion development [12]. The report
of a TOF-like phenotype in mouse models unable to express the
Vegf-164 isoform [14] additionally suggests that VEGF should be a
strong candidate gene for susceptibility to TOF in humans. Given
these considerations, it is perhaps surprising that we demonstrated
no association with CVM in this large study, which was adequately
powered to detect even small effects on risk. However, it remains
possible that severe genetically determined disruptions of VEGF
signalling are sufficiently deleterious to heart formation in man that
affected embryos are non-viable, in which case such alterations
would not be observed in those surviving to birth. We specifically
ruledpatientswith22q11deletionoutofthepresentstudy,therefore
we can neither confirm nor refute the assertion of Stalmans et al.
[12] that the VEGF promoter haplotype is a modifier influencing
the risk of CVM in the setting of 22q11 deletion. It remains possible
that among people sharing the 22q11 deletion genotype, there is a
deletion-related reduction in genetic ‘‘buffering’’ of the differential
activityoftheVEGF gene mediatedbythepromoter variants.Ifthis
were so, the VEGF promoter variants might influence CVM
susceptibility in persons with 22q11 deletion to a greater extent than
they do among those who share the TOF phenotype, but who do
not have such a defect in ‘‘buffering’’. Further studies specifically
examining that hypothesis in larger numbers of patients with 22q11
deletion would be of interest.
Despite the large number of samples we investigated, this study
has certain limitations. While we have taken care to maximise
phenotypic homogeneity among the patients with outflow tract
defects that we studied, focusing on TOF and phenotypes that are
clinically and developmentally closely related, it is not known for
certain whether this group of phenotypes have a common genetic
underpinning. It is therefore possible, though we think it unlikely,
that heterogeneity of genotype/phenotype relationships among
our patients with outflow tract defects reduced the power of this
Table 5. Pooled analysis of rs2010963: G allele of G/C SNP
designated high risk.
Study
No.
Probands OR
95% CI
Low
95% CI
High
Stalmans 58 1.30 0.80 2.00
Lambrechts TOF 148 1.43 1.00 2.02
Lambrechts TGA 40 1.23 0.59 2.56
Vannay 102 0.37 0.24 0.56
Xie Case-Control (all) 222 1.32 1.04 1.68
Xie TDT only 142 1.60 1.16 2.23
Present study TOF patients 595 0.91 0.78 1.08
Present study other CVM 176 1.35 0.97 1.87
All studies* 1341 1.04 0.93 1.16
*Pooled ORs include the entire population of cases and controls from Xie et al.
(2007) rather than the subset of TDT families.
doi:10.1371/journal.pone.0004978.t005
Table 4. Pooled analysis of rs1570360: A allele of G/A SNP
designated high risk.
Study
No.
Probands OR
95%
CI Low
95% CI
High
Stalmans 58 1.80 1.20 2.70
Lambrechts TOF 148 1.46 1.02 2.09
Lambrechts TGA 40 0.94 0.48 1.86
Vannay not typed
Xie Case-Control (all) 222 1.10 0.80 1.53
Xie TDT only 142 0.92 0.58 1.46
Present study TOF patients 595 1.02 0.85 1.21
Present study other CVM 176 1.00 0.75 1.33
All studies* 1239 1.12 0.99 1.26
*Pooled ORs include the entire population of cases and controls from Xie et al.
(2007) rather than the subset of TDT families.
doi:10.1371/journal.pone.0004978.t004
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so if VEGF genotype predisposed to one sub-phenotype within
that group (for example, septal defects), it is unlikely that we would
have detected it. Our SNP analyses were limited to the VEGF
region and 15 Kb either side; therefore, the effects of any long-
range regulatory variants not in significant LD with the SNPs we
typed might have been missed. Although such variants are well
known for several genes, none has yet been described for VEGF to
our knowledge.
Hitherto, there are relatively few studies that have examined
associations between common SNPs and CVM and, perhaps
because of a lack of readily available samples derived from
epidemiological studies, most investigators have studied only small
numbers of patients. This study shows that, in CVM as in other
complex disorders, large sample sizes are of key importance in
obtaining reliable results in genetic association studies. Given the
relative difficulty in establishing large cohorts for CVM (particularly
where particular sub-phenotypes are sought in large numbers), we
suggest that collaborative meta-analyses involving multiple cohorts
are a useful strategy to provide robust information on candidate
genetic susceptibility factors, pending the availability of collabora-
tive genome-wide association study data in large numbers of cases
and controls. Despite our negative findings, it remains possible that
common and rare VEGF genetic susceptibility variants to CVM
exist; however, their effect sizes are likely to be small. Much larger
patient numbers for genotyping and sequencing would be required
to detect such variants, which would be unlikely to have major
impacts on the population burden of disease.
Materials and Methods
Ethics Statement
Ethical approval was given for the study by the Northern and
Yorkshire Multicentre Research Ethics Committee. Fully in-
formed written consent was obtained from all participants (or their
parents, if they were children too young to themselves consent).
The research was conducted in accordance with the Helsinki
declaration.
Study population
Patients with CVM were recruited from collaborating UK
paediatric cardiology centres. Those with clinical diagnoses of
del22q11 syndrome or other known chromosomal abnormalities
were excluded, as were those with other multi-organ malformation
syndromes, learning difficulties, or known maternal exposure to
significant teratogens during pregnancy. Specifically, patients with
tetralogy of Fallot (TOF: EPCC Code 01.01.01), or with the
related conditions pulmonary stenosis/VSD (EPCC Codes
01.01.06 and 01.01.25), and ‘‘Fallot-type’’ double outlet right
ventricle (EPCC Code 01.01.17), who were of European ancestry,
were recruited together with their parents where available as part
of the CHANGE (Congenital Hearts – A National Gene-
Environment Study) programme. Samples from 357 TOF patients
(202 case-parent trios, 81 case-parent duos, 68 single probands
and 3 multiplex families) were genotyped for all selected VEGF
SNPs. An additional 238 TOF probands and available parents (35
Trios, 17 duos, 186 single probands), ascertained using the same
criteria from centres in Nottingham and Oxford were genotyped
at the three previously reported SNPs and rs1547651. Patients of
European ancestry affected by other types of CVM were recruited
in Newcastle. A total of 176 families (50 trios, 66 duos, 60 single
probands) with non-TOF CVM were genotyped (see Table S1 for
case phenotypes). These represented the maximal numbers of
families available for this study for SNP analysis, and enabled us to
more than double the number of cases genotyped in the literature
thus far. Controls were selected from a collection of healthy British
Caucasian families, ascertained through a proband with essential
hypertension, that have been previously described [20]. No control
individual had a history of CVM. A total of 182 unrelated control
individuals were genotyped and included in the association
analysis. A panel of 93 TOF probands from the centres in Bristol,
Leeds and Newcastle were selected for exonic re-sequencing of
VEGF. This number of probands would provide 85% power to
detect at least one mutation that affected the amino acid sequence
or splice sites, if such mutations were present in 2% of TOF cases
or greater. DNA was extracted from blood or saliva samples using
standard protocols.
SNP genotyping
htSNPs were selected for genotyping from within and 15 KB
up- and down-stream of VEGF using the HapMap data for the
samples of Northern and Western European ancestry (CEU
samples: www.broad.mit.edu/mpg/haploview) and the Tagger
utility of Haploview v3.2. Eighteen SNPs with MAF.0.05 were
selected that were in linkage disequilibrium at r
2.0.8 with all
other genetic variation within the region. The SNP rs699947
previously reported to be associated with TOF was among the
selected htSNPs. The other two SNPs typed in previous studies,
rs1570360 and rs2010963, which were not genotyped in the
HapMap, were additionally selected for genotyping. The location
of the SNPs is shown in figure 1.
Seventeen SNPs were genotyped within four iPLEX MALDI-
TOF assays (Sequenom). iPLEX PCR and extension primer
sequences are shown in Table S2. Multiplex PCRs were
performed in 10 ml reactions comprising 1 U Hotstar Taq
(Qiagen), with 3.5 mM MgCl2, 0.5 mM dNTPs (Invitrogen),
0.1 mM of each primer (Metabion) and 20 ng DNA. Thermal
cycling conditions were 95uC for 15 minutes followed by 35 cycles
of 95uC for 20 seconds, 56uC for 30 seconds, 72uC for 1 minute
and a final extension of 72uC for 3 minutes. PCR products were
SAP treated (Sequenom) and iPLEX extension reactions (Seque-
nom) were performed according to manufacturer’s protocols.
Three SNPs (rs1570360, rs699946 & rs866236) were genotyped
using Taqman pre-designed allelic discrimination assays (Applied
Biosystems).
Exon Resequencing
PCR primers were designed within the introns of VEGF based
on transcript NM_003376.3; see Table S3 for PCR primer
sequences and figure 1 for the location of the primers. PCR was
performed in 10 ml reactions comprising 0.25 U Hotstar Taq
(Qiagen), 1.5 mM MgCl2,1 6 Q Solution (Qiagen), 0.8 mM
dNTPs (Invitrogen), 0.5 mM of each PCR primer (Metabion) and
20 ng of DNA. Thermal cycling conditions were 95uC for
15 minutes followed by 35 cycles of 95uC for 45 seconds,
55.5uC for 45 seconds, 72uC for 1 minute and a final extension
at 72uC for 10 minutes. PCR products were cleaned with Exo-
SAP-IT (Amersham) and sequencing reactions performed using
MegaBACE DYEnamic ET dye terminator kit (Amersham)
following manufacturer’s protocols. Sequencing products under-
went isopropanol precipitation and were separated using the
MegaBace 1000 (Amersham). The Staden Package suite of
programs (http://staden.sourceforge.net/) was used to analyse
the sequence traces.
Statistical Analysis
Genotype data was checked for Mendelian consistency within
the families and Hardy-Weinberg equilibrium using PEDSTATS
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PLoS ONE | www.plosone.org 5 March 2009 | Volume 4 | Issue 3 | e4978[21]. Association analysis of the individual SNPs, and of the
previously reported three-SNP haplotype in the VEGF promoter
was performed using UNPHASED version 3.0.9 [22]. UN-
PHASED permits the analysis of datasets containing, as here,
both family-based and case-control data, producing a summary
statistic for all included individuals.
Previous studies that had investigated the relationship between
polymorphisms of VEGF and CVM were sought by Medline
searches using a variety of search string combinations (e.g.
‘‘VEGF’’ and ‘‘congenital heart’’; ‘‘VEGF’’ and ‘‘tetralogy of
Fallot’’), and by hand-searching of reference lists in studies so
identified. Studies utilising either a case-control or a family-based
design were included. For an identified study to be eligible for
inclusion, sufficient information had to be available for the
numbers of cases and controls with each genotype to be deducible
(for case-control studies), or for the numbers of transmitted and
untransmitted risk alleles from heterozygote parents to affected
offspring to be deducible (for studies in family trios). Odds ratios
and 95% confidence intervals were calculated for each SNP in
each study using standard formulae, assuming Hardy-Weinberg
equilibrium and a multiplicative penetrance model [23]. Studies
were combined to produce summary odds ratios and 95%
confidence intervals using an inverse-variance weighting ap-
proach. We prespecified subgroup analyses of the combined data
in patients with TOF and patients with other forms of CVM, in
view of previous published data suggesting a specific effect of
VEGF genotypes on TOF. Since it was not possible to deduce the
three-SNP VEGF promoter haplotype frequencies in all the
identified studies, meta-analysis for the haplotype was not
conducted. We calculated the plausible upper limit of the
population attributable risk (PAR) due to each SNP by substituting
the upper 95% CI of the pooled OR estimate and the frequency of
the risk allele (F) into the equation PAR=F (OR-1)/(F(OR-1)+1).
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